Cayston (aztreonam inhalation solution – Gilead) — Cigna

Initial criteria

• Patient has Pseudomonas aeruginosa in culture of the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture); AND
• Medication is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis

Reauthorization criteria

• Patient was started on Cayston and is continuing a course of therapy

Approval duration

initial: 1 year; continuation: 1 month